NC Capital, LLC v. Metabolomic Technologies, Inc.

CourtDistrict Court, C.D. Illinois
DecidedMarch 29, 2022
Docket4:21-cv-04101
StatusUnknown

This text of NC Capital, LLC v. Metabolomic Technologies, Inc. (NC Capital, LLC v. Metabolomic Technologies, Inc.) is published on Counsel Stack Legal Research, covering District Court, C.D. Illinois primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
NC Capital, LLC v. Metabolomic Technologies, Inc., (C.D. Ill. 2022).

Opinion

UNITED STATES DISTRICT COURT CENTRAL DISTRICT OF ILLINOIS ROCK ISLAND DIVISION

NC CAPITAL, LLC, ) ) Plaintiff, ) ) v. ) Case No. 4:21-cv-04101-SLD-JEH ) METABOLOMIC TECHNOLOGIES, INC., ) ) Defendant. )

ORDER Before the Court are Defendant Metabolomic Technologies, Inc.’s (“MTI”) Motion to Dismiss Plaintiff’s Complaint, ECF No. 10, and Motion for Leave to File a Reply in Support of its Motion to Dismiss, ECF No. 13. For the reasons that follow, the motions are GRANTED. BACKGROUND1 Plaintiff NC Capital, LLC (“NC Capital”) is “a family-owned investment firm that invests in emerging healthcare companies.” Compl. ¶ 1, ECF No. 1. MTI is a Canadian corporation that specializes in metabolomics, or “the measurement of ‘metabolites,’ [which are] small molecules that result from a metabolic reaction found in human specimens.” Id. ¶¶ 2, 8. In May 2019, NC Capital and MTI began discussing NC Capital making an investment in MTI. NC Capital alleges that MTI, through its then-CEO and one of its directors, made misrepresentations “to induce NC Capital to make a substantial investment in MTI.” Id. ¶ 18. The misrepresentations related to MTI’s leading product, PolypDx, a test that MTI represented could “ascertain through a urine sample whether a given patient has pre-cancerous colorectal

1 At the motion to dismiss stage, the court “accept[s] as true all well-pleaded facts in the complaint, and draw[s] all reasonable inferences in [the plaintiff’s] favor.” Pierce v. Zoetis, Inc., 818 F.3d 274, 277 (7th Cir. 2016). Thus, the facts included in the background section are based on the complaint, ECF No. 1. polyps.” Id. ¶ 2. MTI represented that it had finalized an algorithm for detecting “selected urine metabolites that correspond to pre-cancerous colorectal polyps.” Id. ¶ 18. And it represented “that ‘the majority of the work’ in the algorithm was being performed by the selected urine metabolites, as opposed to ordinary demographic and clinical risk factors (like sex, age, and

smoking status) that are observable through a routine check-up.” Id. ¶ 19. Based on these representations, NC Capital committed to invest in MTI. It signed a term sheet on June 2, 2019. “On August 7, 2019, [it] contracted to purchase securities in MTI in two tranches of $ 1 million (USD) each, including warrants of $560,000 upon the funding of the two investment tranches.” Id. ¶ 22. Pursuant to that contract, NC Capital invested $2,560,000 between August 2019 and October 2020. NC Capital currently owns fifteen percent of MTI. In late October and early November 2020, NC Capital learned that MTI’s representations about PolypDx were false. In fact, “ordinary demographic and clinical risk factors, observable by any physician in a routine clinical setting, were doing the bulk of the work in the PolypDx algorithm.” Id. ¶ 28. NC Capital discovered that internal MTI data existing prior to NC

Capital’s investment confirmed this and that MTI scientists had told MTI management in 2012 that the PolypDx algorithm did not primarily rely on metabolites. NC Capital would not have invested in MTI if it had been aware of these facts. NC Capital brings suit against MTI asserting claims under the Securities Exchange Act of 1934, 15 U.S.C. §§ 78a–78qq, and the Illinois Securities Law of 1953, 815 ILCS 5/1–19, a claim that MTI fraudulently induced it to invest in MTI, a claim that MTI negligently made misrepresentations with the intent to induce it to invest, and a claim that MTI was unjustly enriched by its investment. See id. ¶¶ 35–61. MTI moves to dismiss the complaint pursuant to a forum selection clause, for lack of personal jurisdiction, and for failure to state a claim. Mem. Supp. Mot. Dismiss 1–2, ECF No. 11. NC Capital opposes the motion. Mem. Opp’n Mot. Dismiss. 1–3, ECF No. 12. MTI moves for leave to file a reply in support of its motion to dismiss, see generally Mot. Leave Reply, to which NC Capital has filed a response in opposition, Mem. Opp’n Mot. Leave Reply, ECF No. 14.

DISCUSSION I. Motion for Leave to File a Reply For all motions other than summary judgment, “[n]o reply to the response is permitted without leave of Court.” Civil LR 7.1(B)(3). “Typically, reply briefs are permitted if the party opposing a motion has introduced new and unexpected issues in his response to the motion, and the Court finds that a reply from the moving party would be helpful to its disposition of the motion.” Shefts v. Petrakis, No. 10-cv-1104, 2011 WL 5930469, at *8 (C.D. Ill. Nov. 29, 2011). A court may also permit a reply “in the interest of completeness.” Zhan v. Hogan, Case No. 4:18-cv-04126-SLD-JEH, 2018 WL 9877970, at *2 (C.D. Ill. Dec. 18, 2018). MTI seeks leave to file a reply to address new evidence submitted by NC Capital—an

expert report about Canadian law and a declaration from a member of NC Capital regarding facts relevant to personal jurisdiction, see Mot. Leave Reply ¶¶ 5–7—and to respond to NC Capital’s arguments about Canadian law and provide the Court with the underlying authorities cited by NC Capital’s expert, id. ¶¶ 8–9. It states that it “did not address Canadian law in its opening brief because NC[ Capital] did not allege in the Complaint that Canadian law applied.” Id. ¶ 9. NC Capital opposes MTI’s motion, arguing that MTI is attempting to have “a do-over,” going beyond replying to new evidence and arguments and instead “repeat[ing] and attempt[ing] to supplement the arguments [it] made” in the motion to dismiss. Mem. Opp’n Leave Reply 1. Moreover, NC Capital argues that MTI should not have been surprised by NC Capital’s reference to Canadian law because the forum selection clause MTI seeks to enforce directly follows a choice of law clause indicating that the agreement containing the forum selection clause is governed by Canadian law. Id. at 1–2. While the Court agrees that MTI could have addressed Canadian law in the motion to

dismiss, it would be helpful for the Court to consider the Canadian cases MTI attaches to its proposed reply and its argument regarding interpretation of the forum selection clause under Canadian law. Thus, in the interest of completeness, the Court GRANTS the motion for leave to file a reply. The Clerk is directed to file the reply, ECF No. 13-1, on the docket. II. Motion to Dismiss MTI moves to dismiss the complaint on three bases: first, that the parties are bound to litigate this claim in Alberta, Canada under a forum selection clause; second, that the Court lacks personal jurisdiction over it; and third, that NC Capital’s complaint fails to state a claim. Mem. Supp. Mot. Dismiss 1–2. NC Capital responds that the forum selection clause must be interpreted under Canadian law and is not broad enough to cover the claims in this suit, that the

Court does have personal jurisdiction over MTI, and that its complaint states a claim. Mem. Opp’n Mot. Dismiss. 1–3. As the Court finds that the complaint must be dismissed because of the forum selection clause, it does not address MTI’s alternate arguments. The Subscription Agreement between the parties, under which NC Capital agreed to purchase stock in MTI, contains a provision with a forum selection clause and a choice of law clause. See Subscription Agreement, Terms and Conditions ¶ 14, Mem. Supp. Mot. Dismiss Ex. B, ECF No. 11-1 at 7–41.2 In full, it provides:

2 In addition to the allegations in the complaint itself, a court can consider “documents attached to the complaint, documents that are critical to the complaint and referred to in it, and information that is subject to proper judicial notice” when ruling on a motion to dismiss. Geinosky v.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
NC Capital, LLC v. Metabolomic Technologies, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/nc-capital-llc-v-metabolomic-technologies-inc-ilcd-2022.